Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Free Cash Flow (2016 - 2025)

International Stem Cell (ISCO) has disclosed Free Cash Flow for 16 consecutive years, with $46000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 79.09% to $46000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$139000.0, a 267.47% decrease, with the full-year FY2024 number at -$153000.0, down 118.02% from a year prior.
  • Free Cash Flow was $46000.0 for Q3 2025 at International Stem Cell, up from -$332000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $439000.0 in Q2 2023 to a low of -$394000.0 in Q1 2021.
  • A 5-year average of -$18052.6 and a median of $46000.0 in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 881.08% in 2021, then skyrocketed 973.91% in 2023.
  • International Stem Cell's Free Cash Flow stood at -$326000.0 in 2021, then skyrocketed by 124.23% to $79000.0 in 2022, then surged by 103.8% to $161000.0 in 2023, then plummeted by 146.58% to -$75000.0 in 2024, then surged by 161.33% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Free Cash Flow are $46000.0 (Q3 2025), -$332000.0 (Q2 2025), and $222000.0 (Q1 2025).